

UCSF Fetal Treatment Center 1855 4th Street Room A-2432 San Francisco, CA 94158 800-793-3887 fetus.ucsf.edu Northern California Comprehensive Thalassemia Center 747 52nd Street

747 52nd Street Oakland, CA 94609 510-428-3347 thalassemia.com

Prenatal Screening for Hemoglobinopathies

Thalassemias are inherited anemias caused by variants in either the alpha or beta globin genes that result in decreased hemoglobin synthesis. If both parents carry variants in the same globin gene each of their children has a 25% chance of inheriting a severe form of that thalassemia. Both alpha and beta thalassemia major require treatment with serial blood transfusions. Alpha thalassemia major is unique in that treatment, if pursued, should be initiated prenatally.

Sickle cell disease (SCD) is another inherited anemia caused by having two S (sickle) variants in the beta globin gene. Inherited anemias are also caused when one sickle variant and one beta thalassemia or other beta globin variant occur together. Patients may experience recurrent pain episodes and are at risk for infection, pulmonary, neurological, and other complications.

Globally, 5% of people carry a thalassemia trait. For people whose ancestry traces to Asia, the Pacific Islands, the Mediterranean, the Middle East, Latin America or Africa are at greater risk for being carriers.



	BETA THALASSEMIA AND SICKLE CELL ANEMIA	ALPHA THALASSEMIA
ASYMPTOMATIC	 β Thalassemia Trait (β/-) 1 of 2 functioning beta globin genes Can lead to slight microcytic anemia Parents who are both positive for this trait are at risk for having a child with beta thalassemia major Other β globin related genotypes include Hb E and sickle cell anemia (HB S and Hb C) 	Silent alpha thalassemia carrier (α-/αα or αΤα/αα) 3 of 4 functioning alpha globin genes, asymptomatic • Common associated genotypes include alpha 3.7 deletion and alpha 4.2 deletion α Thalassemia trait either αα/ (deletion of 2 α genes in cis, alpha0 trait) or α-/α- (1 α gene deleted on each chromosome, homozygous alpha+ trait) • Slight microcytic anemia • Couples who are both carriers for α-0 trait are at risk for a pregnancy with alpha thalassemia major • Common α-0 deletions are Southeast Asian (SEA), Filipino (FIL), Thai (THAI) and Mediterranean (MED)
SYMPTOMATIC: NON-TRANSFUSION DEPENDENT	 β Thalassemia Intermedia and E Beta Thalassemia Can include the following genetic variant combinations » Homozygosity for mild β+ thalassemia » Dominant forms of β thalassemia » Compound heterozygosity for β+/β° » Compound heterozygosity for β thalassemia Hb E » Sickle cell anemia including Hb SS, Hb SC, and sickle/beta disease • Coinheritance of β thalassemia with hereditary persistence of fetal hemoglobin • Coinheritance of β thalassemia trait and triplicated or quadruplicated alpha genes (eg αα/ααα or αα/αααα) 	 HbH disease (-α/, deletional HbH disease) 1 of 4 functioning alpha globin genes (3 gene deletion) Moderate, stable anemia Increased anemia during viral infections Non-Deletion Hemoglobin H (/αΤα) 1 of 4 functioning alpha globin genes One parent has α-0 thalassemia trait and the other has alpha gene variant More severe anemia Can present with hydrops, require in utero transfusion May require transfusion support after birth Common alpha gene variant include Constant Spring, Quong Sze, or Poly A mutation.
SYMPTOMATIC: TRANSFUSION DEPENDENT	 β Thalassemia Major also called Cooley's Anemia 0 of 2 functioning beta globin genes Individuals born with beta thalassemia major develop severe anemia during infancy and require regular blood transfusions to survive Some patients are eligible for curative treatment with bone marrow transplant Many individuals with HbE β thalassemia also require regular transfusions 	Alpha Thalassemia Major (ATM) or Hb Bart's Hydrops Fetalis (/) 0 of 4 functioning alpha globin genes • Both parents have α-0 thalassemia trait • Leads to severe anemia in fetuses and is fatal unless treated with in utero blood transfusions • Individuals born with alpha thalassemia major continue to require regular blood transfusions and may be eligible for bone marrow transplant




Hemoglobinopathy Carrier Screening^{1,2,4}

Most couples are unaware of their risk for conceiving a child with thalassemia or SCD. Carrier screening ideally occurs preconception or with the initial prenatal labs by assessing the patient's CBC and hemoglobin electrophoresis. When microcytic anemia is detected, testing for alpha-0 trait is performed because normal hemoglobin electrophoresis/HPLC results do not exclude alpha-0 trait. This additional testing is required for women of Southeast Asian and Chinese ancestry and recommended for the other groups.

Pregnant Woman from High-risk Geographic Ancestry: Southeast Asian, Chinese, South Asian, Pacific Islander, Middle Eastern, Mediterranean, Latin American, African Obtain at first prenatal visit CBC3 Ferritin Hb Electrophoresis with A2 quantification Ferritin <30 ng/mL</p> Iron supplementation Assess: MCV, MCH, Hb Variants, HbA2 MCV <80 or MCH <27 HbA2 >3.5% HbE trait or HbS trait Plus HbA2 ≤3.5%* β-Globin Gene Sequencing α-Globin DNA PCR testing Positive for beta thal trait, HbE trait, HbS trait, or alpha-0-thal trait Paternal Evaluation CBC and Hb Electrophoresis **Both Parents Both Parents** positive for Positive combination of for α-0 beta thalassemia Thalassemia trait or HbE or Trait **HbS Trait** Genetic Counseling

Prenatal Monitoring for ATM (Hb Bart's Hydrops Fetalis)

If alpha-0 thalassemia trait is identified in both parents, education related to options including prenatal diagnosis and pregnancy management is essential. Because fetuses affected with alpha thalassemia major develop severe anemia and hydrops fetalis, monitoring the pregnancy for these complications (below) is necessary to mitigate risk to the mother and adverse sequalae to the fetus



^{*} Presence of HbA2 >3.5% does not exclude co-existing alpha0 thalassemia trait. In individuals of Southeast Asian, Filipino or Chinese descent who have microcytic hypochromic anemia, perform alpha globin gene deletion and common variant studies irrespective of HbA2 level.

This tool is not a replacement for referral to genetic counseling, which may happen at any time in this pathway. Genetic counseling provides guidance for genetic testing and management options for families with pregnancies at risk for severe forms of thalassemia.

The sensitivity and specificity are not definitive and not all carriers will be detected by this screening.

The American College of Ob Gyn recommends all pregnant women have a CBC with assessment of MCV.

^{4.} Rare mutations, such as delta-beta thalassemia, non-

deletional alpha thalassemia, and others, may not be captured in this algorithm. In high-risk cases, or where hemoglobin electrophoresis is abnormal, consultation with a genetic counselor and/or hematologist is recommended.

^{5.} PSV as Middle Cerebral Artery Peak Systolic Velocity).

Prenatal Screening for Hemoglobinopathies



Diagnostic Codes and Parameters				
Complete Blood Count		Iron Studies		
85025	 Hemoglobin <11 g/dL indicates anemia Mean Corpuscular Volume <80 fL indicates microcytic anemia Mean Corpuscular Hemoglobin <27 pg indicates hypochromic anemia 	82728	Serum Ferritin <30 ng/mL indicates iron deficiency anemia with or without thalassemia	
Hemoglobin Analysis		Genetic Analysis		
83021	Hemoglobin Electrophoresis/HPLC Hb A2 >3.5% indicates beta thalassemia trait ≤3.5% rules out beta thalassemia but does exclude alpha thalassemia	81364	Beta Globin Complete Gene Sequencing	
		81257	Alpha Globin Common Deletions/Mutations Analysis If negative, consider alpha globin gene sequencing	
Imaging for ATM (Hb Bart's Hydrops Fetalis)		Thalassemia diagnosis ICD-10 Codes		
76811	Fetal Ultrasound to assess for signs of hydrops or evidence of alpha thalassemia major	D56.3	Diagnosis of Parental Alpha or Beta Thalassemia Trait	
		D56.0	Diagnosis of Alpha Thalassemia Major	
76821	Middle Cerebral Artery Doppler Ultrasound MCA peak velocity >1.5 MoM indicates fetal anemia	D56.1	Diagnosis of Beta Thalassemia Major	
		O35.8XX0	Maternal care for suspected fetal condition	
76816	Follow-up fetal ultrasound for hydrops surveillance			

